Oxybuprocaine (Novesine)
Oxybuprocaine
Sandoz South Africa (Pty) Ltd
Registration
- Applicant
- Sandoz South Africa (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Novesine 1 % ointment EACH 100 G OINTMENT CONTAINS OXYBUPROCAINE HYDROCHLORIDE A 1,00 G | 1 %Ointment | G2756 | Old Medicine | Not determined | None |
| Novesine 1 % solution EACH 1 ML SOLUTION CONTAINS OXYBUPROCAINE HYDROCHLORIDE A 0,010 G | 1 %Solution | G2757 | Old Medicine | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Oxybuprocaine
- when intended for ophthalmic or parenteral use;
- except when contained in eye drops intended for the emergency treatment of “arc eyes”. (S2)
Consolidated Schedules 06 July 2026, lines 7437 to 7441
S2: Oxybuprocaine
- when contained in eye drops intended for emergency treatment of arc eyes.
Consolidated Schedules 06 July 2026, line 2474
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
2-(Diethylamino)ethyl 4-amino-3-butoxybenzoate
Drag to rotate. Structure from PubChem CID 4633.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.